Ultimate Guide to FDA Cybersecurity Labeling 2025
Post Summary
The FDA's 2025 cybersecurity labeling rules are a game-changer for medical device manufacturers. These regulations require clear, standardized labeling to help healthcare organizations securely use and maintain devices. The focus is on transparency about device communication interfaces, third-party software, and security updates. Compliance is mandatory for devices with software or internet connectivity, with strict requirements like a Software Bill of Materials (SBOM) and clear patching instructions.
Key takeaways:
- Who needs to comply: Medical device manufacturers, especially those with internet-connected or programmable devices.
- What’s required: Details on communication interfaces, SBOMs, secure configuration steps, and lifecycle updates.
- Why it matters: Failing to meet these requirements can lead to regulatory penalties, recalls, or patient safety risks.
For AI-enabled devices and "cyber devices", additional rules apply, including managing AI-specific risks and disclosing unresolved vulnerabilities. Manufacturers must also keep labeling updated as threats evolve, ensuring healthcare providers can manage risks effectively. These rules are now legally enforceable and essential for protecting patients and maintaining regulatory compliance.
A Quick Primer on FDA's Final Guidance for Cybersecurity in Medical Devices
sbb-itb-535baee
Core Elements of FDA Cybersecurity Labeling Requirements
The FDA's 2025 guidance zeroes in on the technical aspects of cybersecurity labeling, aiming to help IT and security teams safely integrate and maintain medical devices. With research showing that 88% of healthcare cyberattacks involve an Internet of Medical Things (IoMT) device [3], these labeling requirements are a critical defense tool. Let’s break down the key areas manufacturers must address to meet compliance.
Communication Interfaces and Connectivity Transparency
Manufacturers are required to provide a detailed list of all communication pathways a device uses. This includes physical ports (like Ethernet and USB), wireless connections (such as Wi-Fi and Bluetooth), and logical interfaces (like APIs and cloud connections). Even interfaces that are disabled by default or planned for future use must be disclosed, giving healthcare organizations a complete view of the device's potential vulnerabilities.
Technical specifics - like protocols (e.g., TCP/IP, SNMP), necessary ports, and services - should be included to assist IT teams in setting up firewalls and segmenting networks effectively. A recent FBI report revealed that 53% of digital medical devices have exhibited critical vulnerabilities [3]. Using quick-reference tables for this information can streamline IT configuration processes.
"A failure to disclose all of the communication interfaces or third-party software could fail to convey potential sources of risks." – FDA Guidance [1]
Software Bill of Materials (SBOM) Compliance
For devices regulated under Section 524B, manufacturers must include a clear summary of third-party software components and provide instructions for accessing the full, machine-readable Software Bill of Materials (SBOM). These SBOMs must follow industry standards like SPDX or CycloneDX, aligning with NTIA baseline attributes [4][5].
Modern medical devices often incorporate hundreds of third-party software components, with a 2025 audit finding that 64% of open-source components in commercial codebases are transitive dependencies - libraries pulled in automatically by other libraries [4]. The labeling must detail software versions, support levels, end-of-support dates, and known vulnerabilities (CVEs). This enables healthcare providers to quickly assess the impact of newly discovered vulnerabilities on their deployed devices. Starting October 1, 2025, the FDA will reject submissions that lack the required SBOM data [4].
Secure Configuration and Patching Guidelines
In addition to listing components, manufacturers must provide clear guidelines for securely configuring and maintaining devices. This includes deployment steps like setting up authentication (passwords, multi-factor authentication), role-based access control, and network configurations.
Patching instructions need to cover how updates are delivered (over-the-air or local), how to verify updates (e.g., digital signatures), expected downtime, and rollback procedures in case of issues. If any vulnerabilities cannot be fully mitigated, manufacturers must identify them and suggest practical compensating controls, such as enhanced monitoring or access restrictions, to manage risks. This level of transparency allows healthcare organizations to make informed decisions about device security and third-party risk management.
"Labeling that does not include sufficient information to explain how to securely configure or update the device may limit the ability of end users to appropriately manage and protect the medical device system." – FDA Guidance [1]
Lifecycle Management and Ongoing Labeling Updates
Keeping device labeling up to date is a critical part of managing cybersecurity risks throughout a device's lifecycle. Unlike static manuals of the past, cybersecurity labeling must adapt to evolving threats, updates, and changes in devices. Manufacturers are shifting toward event-driven updates, supported by regular reviews, typically every quarter or six months [3]. Let’s break down the key triggers for updates, the responsibilities manufacturers bear, and the risks associated with outdated labeling.
When Labeling Needs an Update
Several events can trigger the need for labeling updates during a device's lifecycle. These include:
- Discovery of new vulnerabilities (CVEs) in third-party software or device code.
- Release of security patches or firmware updates, including details on how updates are delivered, verified, and rolled back.
- Changes in secure configuration practices or hardening instructions.
- Deprecation of older protocols or operating systems.
- Adjustments to end-of-support timelines.
- Cybersecurity-impacting modifications, such as new communication interfaces or altered data flows.
In short, any significant change that affects a device's security posture requires an update to its labeling.
Manufacturer Responsibilities
As of March 29, 2023, manufacturers are legally required to maintain accurate cybersecurity labeling under Section 524B of the FD&C Act [2]. This moves labeling from a "nice-to-have" recommendation to a legally enforceable obligation. Compliance must align with the Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 standards [6].
Key responsibilities include:
- Clearly defining the "Support Life" of each device, so users know how long they’ll receive security updates [7].
- Cross-referencing Software Bill of Materials (SBOMs) with public vulnerability databases, like NVD or GitHub.
- Updating Vulnerability Exploitability eXchange (VEX) documents when new CVEs are discovered, ensuring healthcare providers aren’t chasing vulnerabilities irrelevant to their devices [7].
This proactive approach ensures labeling remains a reliable source of information, helping users address real risks while avoiding unnecessary confusion.
Risks of Falling Behind on Labeling
Outdated labeling isn’t just a regulatory issue - it poses serious risks to patient safety. If healthcare IT teams rely on inaccurate labeling, they might deploy devices with insecure configurations or miss critical patches, leaving systems vulnerable. A stark example is the 2017 FDA recall of 500,000 pacemakers. Researchers exposed vulnerabilities that allowed attackers to remotely drain batteries or alter heartbeats, forcing in-person firmware updates [3].
From a regulatory perspective, outdated labeling can result in a device being deemed "misbranded" or even classified as "dangerous to health" [3]. This can lead to delayed market entry, costly recalls, and legal liabilities. For manufacturers, staying on top of labeling updates isn’t just about compliance - it’s a business necessity to avoid these costly pitfalls and protect both users and their reputation.
Additional Requirements for AI-Enabled and Cyber Devices
Building on the core elements of cybersecurity labeling, this section dives into the extra requirements for AI-enabled devices and those classified as cyber devices. These technologies come with unique risks, and as of 2025, the FDA has authorized over 1,000 AI-enabled medical devices. The regulatory framework has been adjusted to address these challenges, making it critical for manufacturers to understand the evolving compliance landscape [8][9].
AI and Machine Learning Security Documentation
For medical devices utilizing AI or machine learning, the labeling must explicitly state the use of AI and clearly define its role, including the inputs it processes and the outputs it generates [11]. Devices with an authorized Predetermined Change Control Plan (PCCP) introduce additional complexity. A PCCP allows manufacturers to implement pre-approved AI model updates without needing a new marketing application, but it also requires transparency. Users must be informed about the PCCP, and manufacturers are obligated to provide update summaries that outline the changes made, evidence supporting those changes, and updated usage instructions [8].
"Labeling should inform users the device has an authorized PCCP and, as updates are implemented, explain what changed and how to use the device safely." - Charley F. Brown and Gregory Szewczyk, Partners, Ballard Spahr [8]
Labeling must also specify the intended users, their required training, the clinical workflow, and how the AI's automation compares to standard care practices [11]. These requirements are further emphasized for devices classified under Section 524B.
Cyber Devices Under Section 524B
Under Section 524B of the FD&C Act, "cyber devices" are defined as those incorporating software, connecting to the internet or other networks (directly or indirectly), and possessing characteristics that make them vulnerable to cybersecurity threats [13][14]. These devices must include a postmarket vulnerability management plan, cybersecurity assurance processes, and a complete Software Bill of Materials (SBOM) [13].
For AI-enabled devices, the SBOM expands into an AI Bill of Materials (AIBOM), which tracks machine learning-specific dependencies. The AIBOM must cover all software components, including commercial, open-source, and off-the-shelf tools [9][12]. Manufacturers are required to provide a summary of third-party components within the labeling and clear instructions for authorized users to access the full SBOM [3].
Additionally, cyber devices must disclose any known but unresolved vulnerabilities. This includes identifying specific Common Vulnerabilities and Exposures (CVEs) that remain unpatched, explaining their potential safety impact, and detailing mitigation plans [12]. Vulnerability Exploitability eXchange (VEX) documents help clarify which SBOM-listed vulnerabilities are exploitable, simplifying audits for hospital IT teams [12].
"AI-enabled medical devices present additional risks that must be considered, ranging from supply chain poisoning to susceptibility to adversarial manipulations." - Firefinch [9]
Since October 1, 2023, the FDA has implemented a "refuse-to-accept" policy for premarket submissions missing the required cybersecurity information under Section 524B [3][13]. This marks a new level of regulatory scrutiny for cyber devices, signaling the growing importance of robust cybersecurity measures.
How to Implement FDA Cybersecurity Labeling
FDA Cybersecurity Labeling Compliance Checklist for Medical Device Manufacturers 2025
Meeting the FDA's 2025 cybersecurity labeling requirements involves aligning documentation, risk management, and operational practices. Manufacturers and healthcare delivery organizations (HDOs) must ensure cybersecurity transparency is embedded into their quality systems and device lifecycle management.
Compliance Checklist
To meet the requirements, follow this checklist to align your device documentation (like IFUs, manuals, and bulletins) with the FDA's June 2025 labeling expectations. Your labeling must clearly outline security controls in simple terms, covering areas such as authentication, access control, encryption, logging, malware protection, and configuration dependencies [16][10][6].
Additionally, include the security support lifetime - for instance, "security updates provided through December 31, 2031" - to help U.S. hospitals plan budgets and replacement cycles [15]. Provide configuration guidance with secure default settings and network requirements [10][17]. Finally, establish vulnerability reporting channels, such as a dedicated security email or web portal, in line with your coordinated vulnerability disclosure policy [15][12][10].
Integrating Labeling Into Risk Management Practices
Cybersecurity labeling must be closely tied to your risk management system. Labeling should trace back to the risk management file under ISO 14971 and ISO 13485. Design controls should map the journey from identified risks to implemented security measures and then to labeling instructions, ensuring HDOs understand how to operate the device securely [10][6].
For example, when new authentication features are added by your engineering team, update the labeling and IFU content immediately to prevent confusion for users and auditors [10][6]. Use postmarket processes like vulnerability monitoring and incident response to prompt labeling updates when new high-impact vulnerabilities emerge. These updates might include temporary workarounds or secure configuration recommendations, ensuring that operational controls - such as "requires firewall rules" or "requires regular log review" - are clearly communicated [12][6].
Using Censinet for Streamlined Compliance
A centralized platform can simplify these processes. Censinet RiskOps™ acts as a hub for managing FDA cybersecurity labeling compliance while transforming healthcare third-party risk management. HDOs can use the platform to incorporate SBOM data, connectivity details, support lifetimes, and configuration guidance directly into vendor risk assessments and device onboarding workflows.
As security support lifetimes approach expiration, RiskOps™ helps HDOs plan budgets in U.S. dollars for device replacement or extended support [15]. For vendors, Censinet RiskOps™ ensures security controls are traced throughout the device lifecycle, aligning with FDA quality system expectations. This reduces the risk of underspecified support lifetimes or misaligned security documentation - issues that can confuse both users and auditors [15][10][6]. By consolidating labeling data into real-time dashboards, the platform connects FDA compliance with medical device security programs and regulatory reporting, making it easier to meet both operational and regulatory demands.
Conclusion and Key Takeaways
The FDA's 2025 cybersecurity labeling requirements represent a significant shift in how medical device security is managed, with the ultimate goal of protecting patient safety. In an era of increasing cyber threats, these labeling standards are not just a formality - they are essential for safeguarding patients.
Summary of Core Elements
Effective cybersecurity labeling must address key security measures to counter evolving threats. This includes:
- Transparency about all communication interfaces (wired, wireless, and logical).
- A Software Bill of Materials (SBOM) summary that links to comprehensive component lists.
- Detailed hardening instructions covering areas like authentication, role-based access control, and network segmentation.
Additionally, manufacturers need to provide clear patch management procedures, outlining delivery methods, steps to verify update integrity, and rollback processes in case an update fails [3][1].
Labeling must also adapt to new vulnerabilities and configuration changes over time. Failing to meet these requirements could result in a device being classified as misbranded under the FD&C Act (§502(f) and §502(j)), leading to enforcement actions and heightened liability risks [3][1].
The Role of Risk Management in Cybersecurity Labeling
Cybersecurity labeling should be closely tied to a manufacturer’s risk management practices. Each security measure outlined in the labeling must directly address risks identified in the risk management file. This alignment ensures that labeling instructions are not just compliance-driven but also enhance device safety.
For healthcare delivery organizations, this means having the information needed to operate devices securely and apply compensating controls, like network segmentation, to manage residual risks. A strong connection between risk management and labeling is essential for building a reliable compliance framework ahead of 2025 [3].
Preparing for 2025 Compliance
To meet the upcoming requirements, manufacturers should focus on providing:
- Numbered, step-by-step instructions.
- Network diagrams that clearly define trust boundaries.
- Detailed tables outlining ports, protocols, and firewall rules [3].
It’s also critical to disclose any remaining risks and establish patching workflows that minimize operational disruptions.
Tools like Censinet RiskOps™ can streamline compliance efforts by integrating SBOM data, connectivity details, support timelines, and configuration guidance into risk assessments and device onboarding processes. By taking proactive steps now, manufacturers and healthcare organizations can ensure that their cybersecurity strategies prioritize patient safety. Aligning labeling practices with robust risk management will help navigate the challenges of an ever-changing cybersecurity landscape effectively.
FAQs
Does my device fall under FDA Section 524B?
If your device is classified as a medical device and includes features like internet connectivity, updatable software, or network access, it may fall under FDA Section 524B. This section focuses on ensuring a reasonable assurance of cybersecurity for such devices.
To comply, manufacturers must address key requirements, including:
- Providing a Software Bill of Materials (SBOM) to outline all software components.
- Implementing lifecycle security measures to protect the device throughout its use.
- Conducting postmarket vulnerability monitoring to identify and address potential risks after the device is in use.
If your device involves software or connectivity that could impact cybersecurity, it's essential to confirm whether these regulations apply to you.
What should an SBOM include for FDA labeling in 2025?
An SBOM required for FDA labeling in 2025 must contain a machine-readable list of software components. This list should follow the NTIA’s Framing Software Component Transparency guidelines and include key lifecycle details like version, origin, and end-of-support date. These details play a crucial role in enhancing transparency and aiding risk management efforts in premarket submissions.
How often do cybersecurity labels need updating?
Cybersecurity labels need to be refreshed regularly throughout a device's lifecycle. According to the FDA’s 2025 guidance, this involves continuous threat monitoring, implementing updates based on risk, and promptly disclosing vulnerabilities. For instance, labels should be updated within 30 days of identifying a security issue. These regular updates help ensure devices stay secure and meet ever-changing cybersecurity requirements.
